WINDLAS
Windlas Biotech Limited (WINDLAS) Stock Analysis
Windlas Biotech Limited manufactures and markets Ayurvedic and nutraceutical products for domestic consumers. It sells OTC wellness brands through pharmacies and e-commerce in India. The company is a listed healthcare and wellness products firm.
Healthcare › Drug Manufacturers - Specialty & Generic
₹917.40
-3.35% 1W | -1.10% 52W
Market Cap
1.9k CR
P/E Ratio
29.3
52W High
₹1181.9
52W Low
₹697.4
Div. Yield
0.68%
Beta
0.3
50 DMA
₹1028.8
200 DMA
₹866
Profit Margin
7.1%
Inst. Own.
7.2%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 141 | 145 | 153 | 162 | 171 | 175 | 187 | 195 | 203 | 210 | 222 | 233 | 238 |
| Expenses | 124 | 128 | 134 | 142 | 149 | 154 | 164 | 170 | 177 | 184 | 194 | 209 | 213 |
| Operating Profit | 16 | 17 | 19 | 20 | 22 | 21 | 23 | 25 | 26 | 27 | 29 | 24 | 25 |
| OPM % | 12% | 12% | 12% | 13% | 13% | 12% | 12% | 13% | 13% | 13% | 13% | 10% | 11% |
| Other Income | 2 | 3 | 3 | 3 | 4 | 4 | 5 | 4 | 5 | 5 | 4 | 5 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 3 | 3 | 3 | 4 | 6 | 6 | 7 | 8 | 7 | 8 | 8 | 8 |
| Profit before tax | 15 | 16 | 18 | 20 | 23 | 18 | 20 | 20 | 21 | 23 | 24 | 20 | 20 |
| Tax % | 24% | 26% | 23% | 24% | 25% | 26% | 23% | 23% | 22% | 24% | 25% | 25% | 21% |
| Net Profit | 11 | 12 | 14 | 15 | 17 | 13 | 16 | 16 | 16 | 18 | 18 | 15 | 16 |
| EPS in Rs | 5.38 | 5.80 | 6.75 | 7.26 | 8.17 | 6.45 | 7.49 | 7.45 | 7.77 | 8.43 | 8.45 | 7.12 | 7.58 |
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 352 | 307 | 329 | 428 | 466 | 513 | 631 | 760 | 904 |
| Expenses | 313 | 270 | 295 | 373 | 414 | 453 | 553 | 666 | 799 |
| Operating Profit | 39 | 38 | 34 | 55 | 52 | 60 | 78 | 94 | 105 |
| OPM % | 11% | 12% | 10% | 13% | 11% | 12% | 12% | 12% | 12% |
| Other Income | 4 | 54 | 2 | -19 | 7 | 10 | 13 | 18 | 18 |
| Interest | 6 | 5 | 3 | 1 | 1 | 1 | 1 | 4 | 5 |
| Depreciation | 17 | 11 | 9 | 13 | 12 | 12 | 13 | 28 | 31 |
| Profit before tax | 20 | 76 | 25 | 22 | 46 | 57 | 77 | 80 | 87 |
| Tax % | 44% | 16% | 34% | 28% | 16% | 25% | 25% | 24% | 24% |
| Net Profit | 11 | 64 | 16 | 16 | 38 | 43 | 58 | 61 | 66 |
| EPS in Rs | 7.04 | 35.07 | 8.91 | 8.70 | 17.48 | 20.04 | 27.98 | 29.10 | 31.49 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 20% | 20% | 20% | 20% | 20% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 21.0% | 16.0% | – |
| Profit CAGR | 17.0% | 16.0% | – |
Shareholding Pattern
Promoters61.98%
FIIs1.11%
DIIs11.44%
Public25.48%
Promoters61.98%
FIIs0.93%
DIIs11.44%
Public25.64%
Promoters61.90%
FIIs0.60%
DIIs11.80%
Public25.69%
Promoters63.31%
FIIs2.04%
DIIs9.84%
Public24.80%
Promoters63.31%
FIIs2.09%
DIIs7.24%
Public27.35%
Promoters62.37%
FIIs1.32%
DIIs11.61%
Public24.68%
Promoters62.82%
FIIs1.18%
DIIs11.82%
Public24.19%
Promoters62.34%
FIIs1.52%
DIIs10.89%
Public25.25%
Promoters61.90%
FIIs0.60%
DIIs11.80%
Public25.69%
Promoters63.31%
FIIs2.09%
DIIs7.24%
Public27.35%
WINDLAS
Holdings Analysis
Key strengths & risk signals
73
Overall
76
Fundamental
71
Technical
Risks (4)
LOW MARGIN! 7.1% profit margin - thin profits.
RECOVERY MODE! Current price (917.4) above 200-day but below 50-day.
WEAK YEAR! Stock declined 1.1% in the last year.
WEAK MOMENTUM! Limited price growth - -3.4% (1 week), -14.7% (1 month), 8.7% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (1028.8) is above 200-day average (866.0) - positive signal.
BULLISH SENTIMENT! In last 30 days: 8 up days, 20 down days. Avg volume on up days: 147,094 vs down days: 94,264. Ratio: 1.56x
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
Fundamental & Technical Analysis
73Overall
76Fundamental
71Technical
Fundamental Breakdown
Growth Quality
28/30
Revenue CAGR: 20.7% (EXCELLENT, 15/15). Profit CAGR: 16.0% (VERY GOOD, 13/15).
Profit Margin
3/10
LOW MARGIN! 7.1% profit margin - thin profits.
PEG Valuation
8/10
FAIRLY VALUED! PEG of 1.83 indicates reasonable valuation.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.68% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 24.85% public ownership - balanced ownership structure.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (1028.8) is above 200-day average (866.0) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (917.4) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
3/10
WEAK YEAR! Stock declined 1.1% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 8 up days, 20 down days. Avg volume on up days: 147,094 vs down days: 94,264. Ratio: 1.56x
RSI
4/5
APPROACHING OVERSOLD! RSI at 30.1 - watch for reversal.
52W Range
3/5
MID RANGE! Trading at 45.4% of 52W range - neutral zone.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -3.4% (1 week), -14.7% (1 month), 8.7% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
WINDLAS
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-14 | Concall PDF | |
| Q4FY262026-05-28 | Concall PDF | |
| Q3FY262026-02-11 | Concall PDF | |
| Q2FY262025-11-11 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WINDLAS | ₹917.40 | 29.3 | 7.1% | 20.7% | 16.0% | -1.1% | 73 | BREAKDOWN | 0.0% | +10.6% | +18.1% | +4.0% |
| HESTERBIO | ₹2,236.50 | 13.9 | 41.6% | 7.7% | 27.8% | +25.9% | 77 | BOUNCE FROM SUPPORT | +491.5% | +506.3% | -8.2% | -22.9% |
| BETA | ₹1,783.00 | 26.3 | 11.1% | 19.2% | 10.5% | -2.7% | 68 | CONSOLIDATING DOWN | +35.0% | +75.6% | +25.2% | +33.5% |
| SAKAR | ₹961.70 | 69.9 | 13.3% | 22.0% | 23.0% | +190.4% | 73 | BREAKDOWN | +112.8% | -9.1% | +38.5% | +2.7% |
| SYNCOMF | ₹21.90 | 23.4 | 17.2% | 29.4% | 56.2% | +31.7% | 79 | APPROACHING SUPPORT | +57.0% | -1.6% | +7.4% | -7.3% |
| VENUSREM | ₹1,719.50 | 22.4 | 13.4% | 11.6% | 57.0% | +264.9% | 74 | BREAKDOWN | +126.2% | +85.5% | +31.2% | +43.9% |
| INDOCO | ₹245.70 | 767.7 | 0.3% | 3.0% | – | -15.5% | 58 | BREAKDOWN | -281.6% | -400.9% | +8.2% | +2.3% |
| AMRUTANJAN | ₹513.80 | 27.5 | 10.6% | 9.9% | 13.3% | -30.2% | 62 | BREAKOUT | -47.0% | -72.8% | +9.6% | -31.2% |
Data from TradeAlone · Updated daily
WINDLAS News
Windlas Biotech Limited (windlas) Reports its H1 & Q2 FY27 Financial Results: Record Revenue and Profitability Milestones2026-11-05Windlas Biotech Limited (windlas) Q2 & H1fy27: Revenue Surges 19% Yoy to Rs. 264 Crore2026-11-05Windlas Biotech Limited (windlas) Q1fy27: Revenue Streak Extends to 14 Quarters with 18% Yoy Growth2026-08-10Windlas Biotech Limited (windlas): Q4 & FY26 Results: Revenue Up 18%, EPS at Rs. 31.602026-05-21
